Zhang et al. found that NRG1 secreted by stromal cells in tumor milieu promote antiandrogen resistance activating HER3 signaling in prostate cancer cells and the blockade of the NRG1/HER3 axis can re-sensitize cancer cells to antiandrogen therapy [35]. The gene discussed is ERBB3; the disease is neoplasm.